Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Wellington Partners expands its Venture Partner network
Clinical expert Dr. Melvin K. Spigelman augments Life Science team prior to fundraising

Munich, August 24, 2005. With Dr. Melvin K. Spigelman (55), Wellington Partners is gaining a seasoned manager in the field of clinical development and regulatory affairs as a new Venture Partner. Dr. Spigelman and the venture capital firm have already worked together on selected projects since December 2003. As a Venture Partner, Dr. Spigelman will advise Wellington Partners’ Life Science portfolio companies, support Wellington in selecting new investments and take board seats. From his base in New York, Dr. Spigelman’s particular focus will be on providing support to portfolio companies with respect to clinical development and approval in the United States, as well as on forging partnerships with U.S. companies. “The U.S. market stands for 50 percent of the world pharma market. With Mel Spigelman, we now have a seasoned, outstandingly networked Venture Partner in the U.S.,” notes Wellington Partner Dr. Rainer Strohmenger.

As a director of the Global Alliance for TB Drug Development, a non-profit New York organization, Dr. Spigelman is responsible for research and development in the battle against tuberculosis. He had previously held executive positions at BASF Pharma USA from 1989 to 2001, most recently as Vice President Global Clinical Centers. One of his responsibilities in this function was to design the approval studies for Humira™, the first fully human monoclonal antibody for the treatment of rheumatoid arthritis, today a blockbuster product. “Like virtually no one else, Mel Spigelman possesses solid expertise in the design and execution of clinical studies. It is precisely in this phase that our portfolio companies can generate the greatest added value, which means that he perfectly complements our own know-how,” explains Wellington Partners founder Rolf Christof Dienst. He is convinced that winning Dr. Spigelman represents a further major element in current fundraising activities for Wellington’s Life Science fund, with its target volume of € 100 million.

About Wellington Partners
Wellington Partners, formed in 1991, invests in start-ups throughout Europe in the fields of information and communication technology and life science, and numbers among Europe’s most successful early-stage investors. The Munich-based company today manages a total fund volume of € 400 million.

To date, Wellington Partners has invested in over 75 companies and has sold 23 of them at a profit, in four cases through an IPO. Serving as the lead or co-lead-investor, the company has already accompanied e.g. Chipbroker ACG or biotech player Actelion in their IPO, and sold e.g. WLAN AG to Swisscom and the German auctioneer Alando to eBay. Further information:

Publisher Contact Information:

Wellington Partners Venture Capital GmbH
Tel: +49 (0) 89 219941-0

Company profile of Wellington Partners
Past press releases of Wellington Partners.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.